Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes

摘要: With the advent of dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over past decade, incretin therapy has become established as an important treatment strategy for Type 2 diabetes mellitus (T2DM), with efficacy safety profile distinct from that other anti-hyperglycemic agents. However, our understanding optimal clinical use incretins remains incomplete. This review focuses on GLP-1 RAs in T2DM, reference to differing dominant mechanisms action between short- long-acting implications this difference. The role effects various organs than pancreas will also be discussed.